|
Q2 FY2026
As of Jun 27, 2026
|
Q1 FY2026
As of Mar 28, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 27, 2025
|
Q2 FY2025
As of Jun 28, 2025
|
Q1 FY2025
As of Mar 29, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 28, 2024
|
Q2 FY2024
As of Jun 29, 2024
|
Q1 FY2024
As of Mar 30, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jul 1, 2023
|
Q1 FY2023
As of Apr 1, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Oct 1, 2022
|
Q2 FY2022
As of Jul 2, 2022
|
Q1 FY2022
As of Apr 2, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Oct 2, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash, current | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Restricted cash, non-current | ||||||||||||||||||||
| Property, plant, and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Prepaid lease costs, non-current | ||||||||||||||||||||
| Other non-current assets, net | ||||||||||||||||||||
| Investment in unconsolidated joint venture | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued bonus | ||||||||||||||||||||
| 2027 Notes | ||||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Accrued litigation expenses | ||||||||||||||||||||
| Accrued litigation settlement | ||||||||||||||||||||
| Short-term finance lease liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term liabilities: | ||||||||||||||||||||
| Notes, net | ||||||||||||||||||||
| 2027 Notes | ||||||||||||||||||||
| 2030 Notes, net | ||||||||||||||||||||
| Total notes, net | ||||||||||||||||||||
| Delayed draw term loans, net | ||||||||||||||||||||
| Delayed draw term loan warrants at fair value | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Finance lease liabilities | ||||||||||||||||||||
| 2030 Notes Embedded Derivative liability at fair value | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Preferred stock, par value $0.0001 per share — 500,000 shares authorized, none issued and outstanding | ||||||||||||||||||||
| Common stock, par value $0.0001 per share — 3,000,000,000 shares authorized; 515,793,219 shares and 453,688,312 shares issued and outstanding at June 27, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ equity (deficit) | ||||||||||||||||||||
| Total liabilities and stockholders' equity (deficit) | ||||||||||||||||||||
Loading...
